Letter ·
NAMD Urges Congress to Address Break Through Drugs
In October 2014, NAMD called on Congress to provide new tools for states to manage prescription drug costs.
In October 2014, NAMD called on Congress to provide new tools for states to manage the exorbitant costs of specialty drugs entering the market. This letter was triggered by the introduction of curative hepatitis C therapies, which illustrate fundamental challenges in Medicaid drug coverage and reimbursement that need statutory solutions.
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.